News
AI methods for automated identification of regions of inflammation from 99mTc-maraciclatide imaging presented at the World Molecular Imaging Congress 2023
09/09/2023
London, UK, 9th September 2023, Serac Healthcare Limited (“Serac Healthcare” or “the Company”), a clinical radiopharmaceutical company developing innovative molecular imaging technologies, announces that a poster titled “Automatic segmentation of regions of inflammation using deep neural networks for 99mTc-maraciclatide gamma camera imaging of rheumatoid arthritis” is being presented at the World Molecular Imaging Society meeting taking place from 5th to 9th September in Prague, Czech Republic.
Generative Modelling methods for 99mTc-maraciclatide presented at the Institute of Electrical and Electronics Engineers (IEEE) Medical Imaging Conference 2022
10/11/2022
London, UK, 10 Nov 2022, Serac Healthcare Limited (“Serac Healthcare” or “the Company”), the clinical radiopharmaceutical company developing innovative molecular imaging technologies, announces that an abstract titled ‘Single-Shot Generative Modelling for 99mTc-maraciclatide Imaging’ is being presented today at the IEEE Medical Imaging Conference taking place 5-12 November in Milan, Italy.
Serac Healthcare Partners with University of Oxford to Evaluate the Potential of 99mTc-Maraciclatide to Diagnose Endometriosis Non-Invasively
07/06/2022
Serac Healthcare Ltd is working with the University of Oxford to investigate whether an experimental image marker (⁹⁹ᵐTc-maraciclatide) that binds to areas of inflammation can be used to visualise endometriosis using a 20-minute scan.
James McCutcheon FCCA, Appointed Chief Financial Officer
01/11/2021
Please join us in welcoming James to the Serac Healthcare team. James is an experienced commercial and finance director with over 30 years’ experience in the pharmaceutical and medical device sectors, having held senior finance positions in both large multinationals, as well as smaller fast growing SMEs.
Julie Davis, Appointed Head of Quality Management
01/08/2020
Please join us in welcoming Julie to the Serac Life Sciences team as Head of Quality Management. Julie’s career has been spent in life science and radiopharmaceutical drug discovery, most recently consulting with biotech start-ups including leading the development and implementation of operational processes and quality systems.
Jon Barnett PhD, Appointed Head of CMC and Supply Chain
06/07/2020
We are pleased to announce that Jon has joined Serac Healthcare Limited as Head of CMC and Supply Chain. With over 20 years’ experience on radiopharmaceutical and biopharmaceutical product development and commercial supply, Jon has extensive experience of leading global functional and cross-functional project / operational teams to deliver new products and life cycle improvements.
Abstract for Presentation at the European League Against Rheumatism (EULAR) Congress 2020
01/06/2020
Results from a Phase II study evaluating the potential of 99mTc-maraciclatide to image synovial inflammation at the whole-body level will be presented at the European League Against Rheumatism (“EULAR”) Congress 2020. The oral presentation is titled, “IMAGING NEOANGIOGENESIS IN RHEUMATOID ARTHRITIS (INIRA): WHOLE-BODY SYNOVIAL UPTAKE OF A 99MTC-LABELLED RGD PEPTIDE IS HIGHLY CORRELATED WITH POWER DOPPLER ULTRASOUND” and will be delivered by Dr Laura Attipoe, Guy’s and St Thomas’ NHS Foundation Trust, London, UK.
Citation: Ann Rheum Dis, volume 79, supplement 1, year 2020, page 110
Session: Diagnostics and imaging procedures (Oral Presentations)
Druin Burch FRCP, Appointed Chief Scientific Officer (CSO)
01/05/2020
Serac Life Sciences continues to strengthen its management team with the appointment of Dr Druin Burch as Chief Scientific Officer (CSO). Druin is a Consultant Physician at the Oxford University Hospitals NHS Trust, and has three decades experience as a clinician, scientist and writer in the field of developing and testing medical technology.
Abstract for Presentation at the American Congress of Rheumatology (ACR) Congress 2019
07/11/2019
Results from an interim analysis of the first 25 patients enrolled in a study evaluating the potential of 99mTc-maraciclatide to image synovial inflammation at the whole-body level will be presented at the American College of Rheumatology (ACR) Congress. The poster is titled, “IMAGING NEOANGIOGENESIS IN RHEUMATOID ARTHRITIS (INIRA): WHOLE-BODY SYNOVIAL UPTAKE OF A 99MTC-LABELLED RGD PEPTIDE IS HIGHLY CORRELATED WITH POWER DOPPLER ULTRASOUND” and will be presented by Dr Laura Attipoe, Guy’s and St Thomas’ NHS Foundation Trust, London, UK.
Date: Sunday, November 10, 2019
Session Title: Imaging Of Rheumatic Diseases Poster I
Session Time: 9:00AM-11:00AM
Pat Butler, Joins as Board Observer and Advisor.
10/06/2019
Pat, a qualified Chartered Accountant, is a director of Hikma Pharmaceuticals, Chairman of Aldermore Bank and was formerly a Senior Director at McKinsey & Co. He is also a Governor of the British Film Institute and a trustee of the Resolution Foundation.
Serac Healthcare founded to develop a molecular imaging agent to help rheumatologists manage treatment decisions in their patients with rheumatoid arthritis
27/06/2018
Serac Life Sciences Limited (SLS) announces the formation of a new company, Serac Healthcare Limited (SHC), which will develop and commercialise a novel molecular imaging agent for the detection of disease activity in rheumatoid arthritis (RA). SHC, a wholly-owned subsidiary of SLS, has acquired the molecular imaging agent maraciclatide from GE Healthcare. The goal of the company is to enable rheumatologists to “see disease activity” in the joints, informing clinicians and helping them deliver personalised care to their patients.
Title
dd/mm/yyyy